Cameron Turtle Asia-Pacific Vaccine and Immunotherapy Congress 2023

Cameron Turtle

Prof. Turtle trained as a haemato-oncologist in Sydney before completing a PhD in dendritic cell immunotherapy at the University of Queensland and a postdoctoral research fellowship in T cell immunotherapy at Fred Hutchinson Cancer Research Center (FHCRC) in Seattle, USA. He spent 16 years in Seattle and was Professor and Anderson Family Endowed Chair for Immunotherapy at FHCRC, Professor of Medicine at the University of Washington (UW), and an attending physician on the Hematopoietic Cell Transplant and Cellular Immunotherapy Services at Seattle Cancer Care Alliance (SCCA) until 2022. Dr. Turtle has served as Chair of the American Society of Hematology (ASH) Scientific Committee on Transplantation Biology and Cellular Therapies, Co-Chair of the Cellular Immunotherapy for Cancer Working Committee of the Center for International Bone Marrow Transplantation Research (CIBMTR), and Co-Chair of the Seattle Cancer Consortium Cancer Immunology Program. In 2022 he was appointed as CLEARbridge Chair of Cancer Immunotherapy at the University of Sydney. He has led clinical and laboratory research teams conducting multiple investigator-initiated phase 1 clinical trials of genetically modified cellular (CAR-T cell) immunotherapies for patients with haematologic malignancies. His research laboratory in the Charles Perkins Center focuses on understanding the characteristics of distinct human T cell subsets, the development of novel tumor immunotherapies, and factors governing the immune response to cancer.